Epidermal Growth Factor Receptor (EGFR) |

Blog Archives

The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer

Posted on June 30, 2017 by by

Cheng MM, Palma JF, Scudder S, Poulios N, Liesenfeld O Posted in Companion Test, Diagnostic, Personalized Medicine, PubMed Entry, Thasso Post, Theragenomic Medicine No Comments ↓

June 30, 2017 – The below citation from PubMed addresses an vey important issue associated with genetic testing in theragenomic and personalized medicine. It is the question if the genetic test used to stage, classify, or determine treatability of a disease with a given drug is accurate.

…

This is it: First blood test to detect EGFR gene mutations in NSCLC

Posted on June 3, 2016 by by

thassodotcom Posted in Companion Test, Diagnostic, Personalized Medicine, Thasso Post, Theragenomic Medicine No Comments ↓

June 03, 2016 – This is a huge step in the application of theragenomic medicine in cancer patients in the quest to deliver highly individualized health care for patients. Thus, on June 01, the American Food & Drug Administration (FDA) approved the cobas EGFR Mutation Test v2,

…

Osimertinib (Tagrissa) approved for non-smal cell lung cancer (NSCLC) patient subgroup carrying the EGFR T790M mutation

Posted on February 7, 2016 by by

thassodotcom Posted in Allelische Variante, Genetic Predisposition, Personalized Medicine, Pharmacogenetics, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine, Uncategorized No Comments ↓

February 07, 2016 – The European Commission has approved once-daily Osimertinib (Tagrissa) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that is positive for the epidermal growth-factor receptor (EGFR) T790M mutation. This follows a positive review in December 2015.

…

Necitumumab (Portrazza) approved for the treatment of advanced squamous non-small cell lung cancer (NSCLC)

Posted on November 28, 2015 by by

thassodotcom Posted in New Drug Approval, Thasso Post, Theragenomic Medicine No Comments ↓

November 28, 2015 – The American Food and Drug Administration (FDA) just approved Necitumumab (Portrazza) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.

…

Theragenomic medicine: FDA approves Osimertinib (Tagrisso) to treat patients with non-small cell lung cancer (NSCLC) who carry the EGFR mutation T790M

Posted on November 14, 2015 by by

thassodotcom Posted in Genetic Predisposition, New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

November 14, 2015 – The American Food and Drug Administration (FDA) just granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Osimertinib (Tagrisso) was approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.

…

FDA Approves Companion Genetic Diagnostic Test for Erlotinib [Tarceva] in NSCLC

Posted on May 16, 2013 by by

thassodotcom Posted in Allelische Variante, Genetic Predisposition, Personalized Medicine, Thasso Post No Comments ↓

May 14, 2013 – The US Food and Drug Administration (FDA) today announced the approval of the cobas EGFR Mutation Test, a companion diagnostic for the cancer drug Erlotinib (Tarceva). This is the first FDA-approved companion diagnostic that can detect epidermal growth factor receptor (EGFR) gene mutations,

…